ASCO: FDG-PET Has Poor Accuracy for NSCLC Diagnosis Across Many Centers
, June 5, 2012
The use of fluorodeoxyglucose positron emission tomography (FDG-PET), for diagnosing lung cancer may have to be rethought. According to an analysis of data from a national prospective trial, FDG-PET has substantially lower sensitivity and specificity than in previously published studies.
ASCO: Expert Panel Explores Questions Regarding Drug Selection, Drug Sequencing in Advanced Melanoma
, June 3, 2012
The new therapies that became available for advanced melanoma over the past year—the anti-CTLA4 antibody ipilimumab (Yervoy) and the selective BRAF inhibitor vemurafenib (Zelboraf)—represent promising new options for these patients, whose prognosis was heretofore almost universally dismal. However, the advent of new treatment strategies has made treatment decisions more complex.
ASCO: Controversies in Prostate Cancer—PSA Screening
, June 2, 2012
The underlying cost debate surrounding the issue of whether or not to recommend prostate cancer screening is based on the idea that if you use healthcare resources in one area, they’re being diverted from another area by nature of their being a limited pool of funding.